Structure and Activation of the TSH Receptor Transmembrane Domain

Overview

Journal Auto Immun Highlights

Publisher Biomed Central

Date 2016 Dec 7

PMID 27921237

Citations 10

Authors

Ricardo Nunez Miguel

Jane Sanders

Jadwiga Furmaniak

Bernard Rees Smith

Affiliations

Soon will be listed here.

Abstract

Purpose: The thyroid-stimulating hormone receptor (TSHR) is the target autoantigen for TSHR-stimulating autoantibodies in Graves' disease. The TSHR is composed of: a leucine-rich repeat domain (LRD), a hinge region or cleavage domain (CD) and a transmembrane domain (TMD). The binding arrangements between the TSHR LRD and the thyroid-stimulating autoantibody M22 or TSH have become available from the crystal structure of the TSHR LRD-M22 complex and a comparative model of the TSHR LRD in complex with TSH, respectively. However, the mechanism by which the TMD of the TSHR and the other glycoprotein hormone receptors (GPHRs) becomes activated is unknown.

Methods: We have generated comparative models of the structures of the inactive (TMD_In) and active (TMD_Ac) conformations of the TSHR, follicle-stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHR) TMDs. The structures of TMD_Ac and TMD_In were obtained using class A GPCR crystal structures for which fully active and inactive conformations were available.

Results: Most conserved motifs observed in GPCR TMDs are also observed in the amino acid sequences of GPHR TMDs. Furthermore, most GPCR TMD conserved helix distortions are observed in our models of the structures of GPHR TMDs. Analysis of these structures has allowed us to propose a mechanism for activation of GPHR TMDs.

Conclusions: Insight into the mechanism of activation of the TSHR by both TSH and TSHR autoantibodies is likely to be useful in the development of new treatments for Graves' disease.

Citing Articles

Structural basis of signaling regulation of the human melanocortin-2 receptor by MRAP1.

Luo P, Feng W, Ma S, Dai A, Wu K, Chen X Cell Res. 2023; 33(1):46-54.

PMID: 36588120 PMC: 9810661. DOI: 10.1038/s41422-022-00751-6.

Structure of full-length TSH receptor in complex with antibody K1-70™.

Miguel R, Sanders P, Allen L, Evans M, Holly M, Johnson W J Mol Endocrinol. 2022; 70(1).

PMID: 36069797 PMC: 9782461. DOI: 10.1530/JME-22-0120.

Evaluation of analytic and clinical performance of two immunoassays for detecting thyroid-stimulating receptor antibody in the diagnosis of Graves' disease.

Hu Y, Ni J, Cen Y, Zhang B, Wu W, Cheng W J Clin Lab Anal. 2021; 35(12):e23950.

PMID: 34752648 PMC: 8649345. DOI: 10.1002/jcla.23950.

2021 update on thyroid-associated ophthalmopathy.

Neag E, Smith T J Endocrinol Invest. 2021; 45(2):235-259.

PMID: 34417736 PMC: 9455782. DOI: 10.1007/s40618-021-01663-9.

Cryo-EM: A new dawn in thyroid biology.

Coscia F, Taler-Vercic A Mol Cell Endocrinol. 2021; 531:111309.

PMID: 33964321 PMC: 8316605. DOI: 10.1016/j.mce.2021.111309.

References

Sanders P, Young S, Sanders J, Kabelis K, Baker S, Sullivan A . Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. 2011; 46(2):81-99. DOI: 10.1530/JME-10-0127. View

Gromoll J, Partsch C, Simoni M, Nordhoff V, Sippell W, Nieschlag E . A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty. J Clin Endocrinol Metab. 1998; 83(2):476-80. DOI: 10.1210/jcem.83.2.4579. View

Kleinau G, Hoyer I, Kreuchwig A, Haas A, Rutz C, Furkert J . From molecular details of the interplay between transmembrane helices of the thyrotropin receptor to general aspects of signal transduction in family a G-protein-coupled receptors (GPCRs). J Biol Chem. 2011; 286(29):25859-71. PMC: 3138303. DOI: 10.1074/jbc.M110.196980. View

Kruse A, Ring A, Manglik A, Hu J, Hu K, Eitel K . Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature. 2013; 504(7478):101-6. PMC: 4020789. DOI: 10.1038/nature12735. View

Touraine P, Beau I, Gougeon A, Meduri G, Desroches A, Pichard C . New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Mol Endocrinol. 1999; 13(11):1844-54. DOI: 10.1210/mend.13.11.0370. View

Martens J, Verhoef-Post M, Abelin N, Ezabella M, Toledo S, Brunner H . A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: correlation between receptor activity and phenotype. Mol Endocrinol. 1998; 12(6):775-84. DOI: 10.1210/mend.12.6.0124. View

Rasmussen S, DeVree B, Zou Y, Kruse A, Chung K, Kobilka T . Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011; 477(7366):549-55. PMC: 3184188. DOI: 10.1038/nature10361. View

Jaakola V, Griffith M, Hanson M, Cherezov V, Chien E, Lane J . The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science. 2008; 322(5905):1211-7. PMC: 2586971. DOI: 10.1126/science.1164772. View

Jaeschke H, Schaarschmidt J, Eszlinger M, Huth S, Puttinger R, Rittinger O . A newly discovered TSHR variant (L665F) associated with nonautoimmune hyperthyroidism in an Austrian family induces constitutive TSHR activation by steric repulsion between TM1 and TM7. J Clin Endocrinol Metab. 2014; 99(10):E2051-9. DOI: 10.1210/jc.2014-1436. View

10.

Kruse A, Hu J, Pan A, Arlow D, Rosenbaum D, Rosemond E . Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature. 2012; 482(7386):552-6. PMC: 3529910. DOI: 10.1038/nature10867. View

11.

Ring A, Manglik A, Kruse A, Enos M, Weis W, Garcia K . Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Nature. 2013; 502(7472):575-579. PMC: 3822040. DOI: 10.1038/nature12572. View

12.

Okada T, Sugihara M, Bondar A, Elstner M, Entel P, Buss V . The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol. 2004; 342(2):571-83. DOI: 10.1016/j.jmb.2004.07.044. View

13.

Doherty E, Pakarinen P, Tiitinen A, Kiilavuori A, Huhtaniemi I, Forrest S . A Novel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab. 2002; 87(3):1151-5. DOI: 10.1210/jcem.87.3.8319. View

14.

Zhang C, Srinivasan Y, Arlow D, Fung J, Palmer D, Zheng Y . High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012; 492(7429):387-92. PMC: 3531875. DOI: 10.1038/nature11701. View

15.

Park S, Das B, Casagrande F, Tian Y, Nothnagel H, Chu M . Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature. 2012; 491(7426):779-83. PMC: 3700570. DOI: 10.1038/nature11580. View

16.

Manglik A, Kruse A, Kobilka T, Thian F, Mathiesen J, Sunahara R . Crystal structure of the µ-opioid receptor bound to a morphinan antagonist. Nature. 2012; 485(7398):321-6. PMC: 3523197. DOI: 10.1038/nature10954. View

17.

van der Kant R, Vriend G . Alpha-bulges in G protein-coupled receptors. Int J Mol Sci. 2014; 15(5):7841-64. PMC: 4057707. DOI: 10.3390/ijms15057841. View

18.

Trulzsch B, Krohn K, Wonerow P, Chey S, Holzapfel H, ACKERMANN F . Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med (Berl). 2001; 78(12):684-91. DOI: 10.1007/s001090000170. View

19.

Ali M, Latif R, Davies T, Mezei M . Monte Carlo loop refinement and virtual screening of the thyroid-stimulating hormone receptor transmembrane domain. J Biomol Struct Dyn. 2014; 33(5):1140-52. PMC: 4484770. DOI: 10.1080/07391102.2014.932310. View

20.

Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V . Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011; 475(7354):65-70. PMC: 3131495. DOI: 10.1038/nature10236. View